10X Genomics Inc experienced a significant uptick in its stock price, marking a notable shift in investor sentiment.
10X Genomics Inc (NASDAQ:TXG) saw its stock surge by 11.23% in yesterday's trading session, closing at CA$84.11. This increase comes amidst mixed news in the healthcare sector, highlighting the company's resilience and growth potential.
Investor takeaway: The surge in 10X Genomics' stock could signal renewed investor confidence, especially as the company navigates a challenging healthcare landscape.
Advertisement
10X Genomics Inc
TXG.US
TXG.US
10X Genomics Inc
WealthAwesomeMarket cap
$10.96B
52W high
$85.93
52W low
$11.16
1W change
+9.28%
Beta
2.08
Analyst Price Targets
Based on 16 analysts covering TXG · as of Sep 23, 2026
Wall Street analysts forecast TXG stock price to fall 32.7% over the next 12 months.
Consensus
Buy3.75 / 5.00
Avg. Target
C$56.60
-32.7% Upside
Previously C$52.13 on Sep 17, 2026
Current Price
C$84.11
Last close
Analyst Breakdown (16 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TXG's historical volatility
30-Day Vol
65.0%
Annualized
90-Day Vol
73.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$100.55
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$89.27 | C$71.33 – C$111.72 |
| 60 trading days | C$94.74 | C$68.99 – C$130.12 |
| 90 trading days | C$100.55 | C$68.18 – C$148.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
The strong performance of 10X Genomics can be linked to its innovative genomic technologies and growth potential in the rapidly evolving healthcare market. Many investors may view this as a buying opportunity as the company continues to expand its product offerings.
Bear case
Despite the recent surge, 10X Genomics still faces challenges, including a competitive market and regulatory pressures in the healthcare sector. Investors should stay cautious and keep a close eye on the company's performance.
Market Response
Advertisement
The 11.23% increase in 10X Genomics' stock price surprised many investors, especially given the mixed sentiment across the healthcare sector. This surge indicates a strong market response to the company's ongoing developments and growth potential.
Future Prospects
Looking ahead, 10X Genomics is well-positioned to capitalize on the growing demand for genomic technologies. As the healthcare landscape continues to evolve, the company’s innovative solutions may attract further investment, making it a stock to watch in the coming months.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
